Adial Pharmaceuticals, Inc.
$1.63
▼
-2.31%
2026-04-21 05:05:00
www.adial.com
NCM: ADIL
Explore Adial Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.33 M
Current Price
$1.63
52W High / Low
$687.5 / $1.54
Stock P/E
—
Book Value
$4.75
Dividend Yield
—
ROCE
-147.82%
ROE
-1.71%
Face Value
—
EPS
$-11.93
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
1.4
Debt / Equity
—
Current Ratio
4.42
Quick Ratio
4.42
Forward P/E
-0.33
Price / Sales
—
Enterprise Value
$-3.64 M
EV / EBITDA
0.47
EV / Revenue
—
Rating
None
Target Price
$23.33
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 2. | Greenwich LifeSciences, Inc. | $24.52 | — | $384.32 M | — | -631.87% | -5.43% | $34.1 / $7.78 | $0.16 |
| 3. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 4. | Artiva Biotherapeutics, Inc. | $13.39 | — | $310.19 M | — | -76.21% | -56.55% | $13.2 / $1.47 | $4.53 |
| 5. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 6. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
| 7. | Achieve Life Sciences, Inc. | $4.25 | — | $226.27 M | — | -167.79% | -2.58% | $6.03 / $1.95 | $0.4 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -1.89 M | -1.76 M | -1.88 M | -2.27 M | -1.94 M | — |
| Net Profit | -2 M | -1.79 M | -1.96 M | -2.23 M | -2.07 M | — |
| EPS in Rs | -1.4 | -1.26 | -1.37 | -1.56 | -1.45 | -9.5 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -7.8 M | -8.28 M | -6.89 M | -10.86 M |
| Net Profit | -7.98 M | -13.2 M | -5.12 M | -12.73 M |
| EPS in Rs | -5.59 | -9.24 | -3.59 | -8.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 6.67 M | 5.04 M | 4.74 M | 5.73 M |
| Total Liabilities | 1.4 M | 0.98 M | 0.65 M | 2.46 M |
| Equity | 5.28 M | 4.07 M | 4.08 M | 3.28 M |
| Current Assets | 6.18 M | 4.06 M | 3.2 M | 4.78 M |
| Current Liabilities | 1.4 M | 0.98 M | 0.65 M | 1.79 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -6.49 M | -6.92 M | -6.81 M | -11.19 M |
| Investing CF | 0.15 M | 0 M | 1.5 M | 0 M |
| Financing CF | 8.47 M | 7.85 M | 4.13 M | 9.13 M |
| Free CF | -6.49 M | -6.92 M | -6.81 M | -11.19 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -157.59% | 59.76% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-02-06 | 1:0.04 |
| 2023-08-07 | 1:0.04 |